In a CRC-bearing mouse model, YTHDF1-deficient classical DCs presented a better therapeutic effect along with anti-PD-L1 treatment compared with that of the control mice by enhancing the ability of cross-presentation of tumor antigens of DCs and promoting the activation of T cells (154). This evidence concerns the gene YTHDF1 and neoplasm.